Publications by authors named "Emilie Bernichon"

7 Publications

  • Page 1 of 1

Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study.

Authors:
Emilie Bernichon Claire Tissot Sophie Bayle-Bleuez Romain Rivoirard Wafa Bouleftour Fabien Forest Fabien Tinquaut Benoite Mery Pierre Fournel

Bull Cancer 2020 Dec 24. Epub 2020 Dec 24.

Institut de cancérologie Lucien-Newirth, Department of Medical Oncology, 108, bis avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France.

Objectives: Immunotherapy is the current treatment in non-small cell lung cancer (NSCLC). 20% of patients treated with immunotherapy have a prolonged response. What about the remaining 80%? How can we explain that some patients get no benefit from immunotherapy?

Materiel And Methods: We retrospectively analyzed predictive factors of primary or secondary resistance to immunotherapy in NSCLC patients from 2 French hospitals between 2015 and 2018. Moreover, we evaluated whether PD1 inhibitor had an impact on the antitumor effects of salvage chemotherapy administered after immunotherapy. We chose to focus on taxanes.

Results: Ninety-six patients were included in this cohort, 65(68%) patients were considered as having primary resistance and 31(32%) secondary resistance. Resistant populations did not differ. At immunotherapy initiation, median survival was 4.6 months for primary resistant patients (95%CI-4.6-6.8) and 15.6 months (95%CI-9.8-NA) for secondary resistant patients. The disease control rates with taxane were 15% in pre immunotherapy conditions vs 50% in post immunotherapy. Response rates improved regardless of the status of resistance.

Conclusion: This study enriches data about immunotherapy in real-life in NSCLC. Prognostic resistance factors still seem complicated to identify. The high rate of taxane responders in post immunotherapy in this retrospective cohort support the use of taxane in therapeutic escape.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bulcan.2020.10.010DOI Listing
December 2020

Acquired ATRX Loss and ALT Phenotype Through Tumor Recurrences in a Case of Pleomorphic Xanthoastrocytoma Suggest Their Possible Roles in Tumor Progression.

Authors:
Pierre Dal Col Delphine Poncet Romain Rivoirard François Vassal Emilie Bernichon Claire Boutet Michel Péoc'h Fabien Forest

J Neuropathol Exp Neurol 2020 09;79(9):1011-1014

Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire de Saint Etienne, Hôpital Nord, Saint Etienne.

Pleomorphic xanthoastrocytoma (PXA) is classified as an astrocytic glioma occurring most often in children or young adults. Molecular alterations in PXA are not fully known, especially those associated with tumor progression. We describe a patient with several relapses of a PXA. The tumor showed an acquired ATRX loss through tumor evolution. We tested alternative lengthening of telomeres (ALT) with the C-circle test. While the test was negative in the first tumor, a high circle activity was detected in the last relapse, suggesting an acquired ALT phenotype. Our data not only confirm previous findings of the possible occurrence of ATRX mutations in PXA but also suggest that this alteration is linked to PXA progression. In small biopsies, tumors with ATRX loss, without IDH or histone mutation, pathologists should consider the diagnosis of PXA, especially if associated with BRAF V600E mutation, CDKN2A deletion, and ALT.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1093/jnen/nlaa074DOI Listing
September 2020

Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.

Authors:
Edouard Chanal Wafa Bouleftour Aline Guillot Elise Rowinski Emilie Bernichon Lancelot Tremeau Renaud Lardon Bertrand Lacroix Stephane Lorin Gregory Delorme Yves Perraud Corinne Armand Frederic Levigne Alexis Vallard Julien Langrand-Escure Pierre Fournel Mery Benoite Cecile Vassal

Bull Cancer 2019 Dec 30;106(12):1086-1093. Epub 2019 Sep 30.

Institut de cancérologie Lucien-Newirth, Department of Medical Oncology, Saint-Priest-en-Jarez, France.

Background: Testicular Germ Cell Tumors (TGCTs) represent the most frequent malignant tumour among young male adults. Orchiectomy alone cure 80% of stage I. Standard options after orchiectomy include radiotherapy (RT), chemotherapy (CT) by 1 cycle of carboplatin AUC 7 or active surveillance (SV) for seminomatous GCTs (SGCT) and retroperitoneal lymphadenectomy (RPLND), CT by 1 or 2 cycles of Bleomycine Etoposide Cisplatine (BEP) or active surveillance for nonseminomatous GCTs (NSGCT). Adjuvant treatments decrease the relapse rate after orchiectomy with substantial toxicities without any benefit on overall survival. Recent guidelines accorded utmost importance on SV rather than adjuvants strategies. The main objective of this study was to describe our current practice over the 10 past years in regard of these recommendations.

Methods: Data of 50 patients with stage I GCT treated in our institute were collected between 2006 and 2016. Demographic and anatomopathologic data were reported. Clinical practice in our center was analyzed during two periods [2006-2011] and [2012-2016] according to the European Association of Urology Guidelines in 2011.

Results: Patient's median age was 35.3 years. The analysis of clinical practice during the last 10 years showed that in SGCT, main treatment was RT than SV and CT. This option declined over the years (89% between 2006-2010 versus 53% between 2011-2016) whereas SV was more often employed (27% between 2011-2016 versus none between 2006-2010). Surveillance was used for 64% of NSGCT.

Conclusions: In our center, RT was less used over the years for the benefit of SV which is recommended by guidelines.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bulcan.2019.08.012DOI Listing
December 2019

Maintenance Therapy in Metastatic Solid Tumors: Innovative Strategy or Simple Second-line Treatment?

Authors:
Elise Rowinski Pierre Fournel Emilie Bernichon Wafa Bouleftour Nicolas Magné Benoîte Mery

Am J Clin Oncol 2019 08;42(8):615-623

Departments of Medical Oncology.

Managing metastatic diseases involves defining the best strategy that is supposed to take into account both efficacy and quality of life. To this end, clinicians use stop and go or maintenance strategies. As a matter of fact, 2 maintenance strategies can be distinguished: continuation maintenance using a drug already present in induction treatment and switch maintenance with a newly introduced drug. Several drugs have been approved as maintenance therapy with several current indications in solid tumors. Questions remain concerning such strategies, notably duration, cost, tolerability, and shortcut between switch maintenance and early second line. If the concept of maintenance strategy remains trendy with numerous trials ongoing, several issues are still pending. The aims of this review were to accurately define and describe the various facets of maintenance therapy through its several indications in real life and then to discuss the future challenges of maintenance therapy in oncology.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1097/COC.0000000000000574DOI Listing
August 2019

[HPV: Carcinogenic implications and preventive measures].

Authors:
Emilie Bernichon Sophie Espenel Benoite Méry Jane-Chloé Trone Amel Rehalia-Blanchard Yuan Ming He Chloé Rancoule Nicolas Magné

Presse Med 2019 Jul - Aug;48(7-8 Pt 1):756-766. Epub 2019 Jul 12.

Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; Laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, CNRS UMR 5822, 165, chemin du grand Revoyet, BP 12, 69921 Oullins cedex, France. Electronic address:

Human oncogenic papillomaviruses (HPV) have an increasingly prominent role in the genesis of many cancers. The oncogenic mechanisms associated with HPV are now better known and make it possible to explain the etiopathogenesis of the association. HPV status is now sought for certain cancers and conditions both prognosis and management of patients. Preventive antiviral vaccination has become a real public health issue and aims to effectively reduce the prevalence of cervical, anal and oropharynx cancer, HPV-associated. However, vaccination against HPV still lags behind. The purpose of this review is to redefine the involvement of HPV in several cancers as well as current therapeutic challenges of HPV-related cancers, notably in term of prevention.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lpm.2019.05.019DOI Listing
September 2019

Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies.

Authors:
Ming Yuan He Chloé Rancoule Amel Rehailia-Blanchard Sophie Espenel Jane-Chloé Trone Emilie Bernichon Elodie Guillaume Alexis Vallard Nicolas Magné

Crit Rev Oncol Hematol 2018 Nov 12;131:96-101. Epub 2018 Sep 12.

Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270, St Priest en Jarez, France; Cellular and Molecular Radiobiology Laboratory, CNRS UMR 5822, IPNL, 69622, Villeurbanne, France. Electronic address:

Triple-negative breast cancer (TNBC) (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is viewed as an aggressive subgroup of breast cancer. Treating patients with TNBC remains clinically challenging. It's now well established than radiation therapy is able to improve locoregional control in breast cancer patients both after breast conserving surgery or mastectomy, with positive impact in high-risk patients for long-term survival. Biologic characterization of breast tumor different subtypes, in particular the heterogeneous subtype of TNBC could permit to adapt the treatment plan. In the present review, summarizing the molecular types, we describe clinical features and postoperative radiotherapy current situation for TNBC, and we provide new strategies and directions through an adapted radiation therapy.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.critrevonc.2018.09.004DOI Listing
November 2018

[Immunotherapy: Activation of a system not a pathway].

Authors:
Emilie Bernichon Chloé Rancoule Alexis Vallard Julien Langrand-Escure Benoîte Mery Jean-Baptiste Guy Nicolas Magné

Bull Cancer 2017 May 3;104(5):462-475. Epub 2017 May 3.

Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France. Electronic address:

Immunotherapy is on the roll. After revolutionary effects in melanoma, immunotherapy is invading other locations. If current treatments, chemotherapies or targeted therapies block one pathway, immunotherapy should be understood as the activation of a whole system. Indeed, oncogenesis process is defined as an escape of the immune system and the stimulation of this system can block the carcinogenic process. The aim of the present review is to describe the place of immunotherapy in the treatment of solid cancers.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bulcan.2017.03.004DOI Listing
May 2017